日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial

一项多中心、随机、双盲、安慰剂对照的3期临床试验:在初诊晚期卵巢癌患者中,使用氟哌啶醇联合或不联合阿帕替尼作为维持治疗方案的疗效评价(FZOCUS-1):一项多中心、随机、双盲、安慰剂对照试验

Wu, Lingying; Wang, Jing; Li, Qingshui; Wang, Danbo; Zhang, Cuiying; Tang, Junying; Zhang, Guonan; Hao, Min; Yao, Desheng; Gao, Qinglei; Zhang, Youzhong; An, Ruifang; Yin, Rutie; Wang, Li; Xia, Bairong; Zhou, Qi; Yang, Hongying; Zhu, Jianqing; Jiang, Kui; Chen, Zhengzheng; Wu, Qiang; Duan, Wei; Huang, Yi; Zhang, Hui; Wei, Shuqing; Li, Guiling; Meng, Yuanguang; Wang, Ke; Yang, Xinfeng; Huang, Xianghua; Pan, Lingya; Yu, Jinjin; Lou, Ge; Zhang, Yu; Zhou, Huaijun; Guo, Xiaoqing; Yang, Hong; Cheng, Xiaodong; Li, Xiumin; Wang, Wuliang; Zhao, Hongqin; Li, Yunxia; Yang, Yingjie; Lin, An; Cheng, Wenjun; Chen, Lihong; Xie, Xiaoying; Di, Wen; Hu, Yuanjing; Chen, Mo; Wen, Hongwu; Cai, Liping; Wu, Xiaohua; Lin, Zhongqiu; Wang, Quanren; Yang, Xinfeng; Li, Ning

Tenecteplase for Acute Non-Large Vessel Occlusion 4.5 to 24 Hours After Ischemic Stroke: The OPTION Randomized Clinical Trial

替奈普酶治疗缺血性卒中后 4.5 至 24 小时内的急性非大血管闭塞:OPTION 随机临床试验

Ma, Gaoting; Mo, Ran; Zuo, Yingting; Ma, Qingfeng; Zhao, Guangjian; Yao, Xiaoxi; Liang, Ji; Zhou, Li; He, Yong; Long, Faqing; Yuan, Zhengzhou; Liu, Lei; Han, Guosheng; Tan, Yan; Ai, Zhibing; Cai, Chunsheng; Liu, Juan; Zhang, Liyong; Yang, Haihua; Yi, Tingyu; Li, Li; Fu, Yao; Zhang, Yanxing; Shao, Xiangzhong; Yu, Zhipeng; Wu, Saizhen; Du, Yanqiu; Mao, Lingqun; Guo, Hongling; Chen, Xufeng; Chen, Yifei; Zhao, Qiong; Chi, Liyi; Liu, Yi; Zhang, Haochun; Li, Guangzong; Meng, Shujuan; Wu, Yifan; Wu, Jieying; Jiang, Ziying; Lei, Shaoyuan; Gao, Daiquan; Zhong, Lianmei; Fiehler, Jens; Wang, Duolao; Nguyen, Thanh N; Saver, Jeffrey L; Hao, Junwei

Osteoarthritis: molecular pathogenesis and potential therapeutic options

骨关节炎:分子发病机制和潜在治疗方案

Zhang, Yi; Han, Yanqi; Sun, Ying; Hao, Longhui; Gao, Yue; Ye, Jun; Wang, Hongliang; Zhang, Tiantai; Liu, Yuling; Yang, Yanfang

First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial

一线治疗EGFR突变型非小细胞肺癌患者,比较奥莫替尼(EGFR酪氨酸激酶抑制剂)联合阿帕替尼(VEGFR抑制剂)与奥莫替尼单药治疗的疗效:一项随机、多中心、II期临床试验

Zhang, Fan; Zheng, Zhendong; Zhang, Hongmei; Yan, Xiaolong; Liu, Zhefeng; Yang, Fan; Wen, Juyi; Gan, Xin; Wu, Lin; Cang, Shundong; Wang, Hongmei; Zhao, Jun; Peng, Liang; Li, Xiaosong; Fan, Zaiwen; Shen, Ge; Zhou, Qiong; Zou, Jinjing; Xu, Yu; Zhang, Lei; Zhao, Mingfang; Cai, Shangli; Hu, Yi

PRIME-HFrEF Trial: a randomized, double-blind, multi-dose umbilical cord-derived mesenchymal stem cell regimen for heart failure

PRIME-HFrEF试验:一项针对心力衰竭的随机、双盲、多剂量脐带间充质干细胞治疗方案

Han, Wei; Jiao, Yuheng; Chen, Wei; Gong, Xin; Hu, Hao; Xin, Yuanfeng; Guan, Sibin; Zhao, Jun; Zhang, Qi; Yang, Bing; Pan, Jingwei; Wang, Haiyan; Lu, Qing; Chu, Shuguang; Cai, Dihui; Zheng, Liang; Jia, Wenwen; He, Zhiying; Yang, Huangtian; Sun, Yi Eve; Liu, Zhongmin

Efficacy and immunomodulatory effect of Claudin18.2-specific IL-7/XCL1 armored CAR-T cells in digestive tract cancer: preclinical and clinical analysis

Claudin18.2特异性IL-7/XCL1修饰的CAR-T细胞在消化道癌症中的疗效和免疫调节作用:临床前和临床分析

Zhao, Xuan; Liu, Jinyan; Zhang, Zhen; Zhou, Yali; Jin, Shuiling; Zong, Hong; Wang, Feng; Song, Min; Zhong, Yali; Li, Qinglong; Pei, Bo; Yu, Yong; Gao, Ming; Ge, Wengang; Han, Lu; Ren, Jiangtao; Zhang, Yi

Visinin-like protein 1 disrupts calcium homeostasis and promotes atrial fibrillation in human and rodent models

视蛋白样蛋白1破坏钙稳态,并在人类和啮齿动物模型中促进心房颤动。

Xiong, Ke; Wang, Guanghua; Li, Desheng; Shao, Beihua; Chen, Zhiwen; Zou, Qicheng; Zhang, Xinrui; Dong, Yanru; Zhao, Xuxia; Yuan, Yixin; Xu, Hongtao; Liu, Yi; Liang, Dandan; Wang, Li; Zhou, Bin; Dong, Nianguo; Xie, Duanyang; Chen, Yi-Han

Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study

抗PD-1抗体penpulimab联合化疗治疗复发性或转移性鼻咽癌:一项随机、双盲3期研究

Huang, Shuang; Liu, Feng; Qu, Song; Chen, Lisha; Zhou, Ping; Qu, Shenhong; Ai, Xiaohong; Chen, Yong; Liu, Meilian; Wang, Rensheng; Chan, Kelvin Kw; Zhang, Peng; Hu, Chunhong; Wen, Jiyu; Zhang, Jian; Lin, Qin; Li, Xiaojiang; Gu, Kangsheng; Xiang, Li; Wang, Dongxia; Li, Jingao; Lin, Daren; Hu, Desheng; Ding, Jianwu; Wang, Siyang; Huang, Xiaoming; Wang, Lin; Jin, Feng; Pfister, David G; Mak, Milena Perez; Marchi, Pedro Rafael Martins de; Jiang, Yi; Yang, Haihua; Hu, Xiaoye; Liu, Tianrun; Wu, Dehua; Shreenivas, Aditya; Oliveira, Thiago Bueno de; Silva, Carlos Eduardo Baston; Alves, Gustavo Vasconcelos; Li, Xianming; Yao, Zhifang; Lu, Dongmei; Hu, Mingxiu; Wang, Zhongmin Maxwell; Li, Baiyong; Xia, Michelle; Chen, Xiaozhong; Hu, Chaosu; Xu, Tingting

Extraocular delivery of bioswitchable tri-miR-22-loaded tetrahedral DNA nanostructures for intraocular neovascular and neurodegenerative repair.

将载有生物可切换三 miR-22 的四面体 DNA 纳米结构进行眼外递送,用于眼内新生血管和神经退行性病变的修复。

Wang Qiong, Wang You, Chen Li, Huang Junyang, Cai Tao, Lin Yi, Liu Jingying, Liu Jinnan, Zhu Jiang, Li Rong, Luo Delun, Ding Xiaoyan

Employing epigenetic protein degradation techniques to block CCL5-mediated photodynamic therapy via a programmed delivery platform.

利用表观遗传蛋白降解技术,通过程序化递送平台阻断 CCL5 介导的光动力疗法。

Yang Tingting, Hu Yuzhu, Guo Anjie, Zhang Xifeng, Wang Wanyu, Yi Linbin, Zhang Rui, Gou Xinyu, Qian Zhiyong, Wang Bilan, Cheng Yongzhong, Gao Xiang